Gene Solutions披露了AI驱动的癌症检测技术, 使用血液检测来早期发现复发, Gene Solutions unveiled AI-driven cancer detection tech using blood tests to find recurrence earlier, backed by studies and two million tests.

在2025年新加坡肿瘤学学会会议上,Gene Solutions展示了分子残留疾病检测和AI驱动的多工程学的进展,利用循环肿瘤DNA来及早发现癌症复发,指导手术后治疗,实时监测治疗。 At the 2025 Singapore Society of Oncology meeting, Gene Solutions showcased advances in molecular residual disease detection and AI-powered multi-omics, using circulating tumor DNA to enable earlier cancer recurrence detection, guide post-surgical treatment, and monitor therapy in real time. 他们的平台将DNA、RNA和人工智能结合起来,以提高敏感性和识别肿瘤来源,同时对JCO肿瘤学进展和Npj乳腺癌的研究也支持其临床价值。 Their platform combines DNA, RNA, and artificial intelligence to improve sensitivity and identify tumor origins, with studies in JCO Oncology Advances and npj Breast Cancer supporting its clinical value. 该公司通过在新加坡的CAP认证实验室进行了200多万次测试,促进区域合作,并倡导扩大伙伴关系,以在整个亚太推进个性化、数据驱动的癌症护理。 The company, which has conducted over two million tests via a CAP-accredited lab in Singapore, promotes regional collaboration and advocates for expanded partnerships to advance personalized, data-driven cancer care across the Asia-Pacific.